Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Gene Biotherapeutics, Inc. (CRXM)
|
Add to portfolio |
|
|
|
| Price: |
$0.05
| | Metrics |
| OS: |
64.9
|
M
| |
|
|
| Market cap: |
$3.12
|
M
| |
|
|
|
Net debt:
|
$203.4
|
k
| |
|
|
|
EV:
|
$3.33
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($660.4)
|
k
| |
|
|
|
EBIT
|
($662.2)
|
k
| |
|
|
| EPS |
($0.04)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 1.9 | 0.0 | 0.7 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue growth | | -100.0% | 1200.0% | | | | -100.0% | 83.8% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Gross profit | 1.9 | 0.0 | 0.7 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | 100.0% | 100.0% | | | | 36.7% |
| Selling, general and administrative | 1.0 | 0.6 | 0.9 | 1.8 | 2.2 | 2.8 | 2.9 | 4.9 |
| Research and development | 0.2 | 0.2 | 0.3 | 0.3 | 0.6 | 0.4 | 0.6 | 2.0 |
| EBITA | -0.7 | -0.8 | -1.2 | -2.1 | -2.8 | -3.1 | -3.6 | -6.8 |
| EBITA margin | -35.6% | | -179.0% | -4252.6% | | | | -6211.5% |
| Amortization of intangibles | | | | | | | | 0.1 |
| EBIT | -0.7 | -0.8 | -1.2 | -2.1 | -2.8 | -3.1 | -3.6 | -6.9 |
| EBIT margin | -35.6% | | -179.0% | -4252.6% | | | | -6324.4% |
| Pre-tax income | -0.7 | 0.8 | -0.6 | -2.1 | -3.3 | -5.2 | -14.6 | -8.4 |
| Income taxes | 0.0 | 0.0 | -0.1 | -0.2 | -0.3 | -1.5 | -9.1 | -1.5 |
| Tax rate | 0.0% | 0.0% | 21.3% | 9.7% | 9.2% | 28.3% | 62.2% | 18.1% |
| Net income | -0.5 | 0.9 | -0.4 | -1.9 | -3.7 | -4.3 | -5.5 | -9.3 |
| Net margin | -27.8% | | -66.9% | -3788.3% | | | | -8534.9% |
| |
| Diluted EPS | ($0.02) | $0.06 | ($0.03) | ($0.13) | ($0.28) | ($0.34) | ($0.50) | ($1.33) |
| Shares outstanding (diluted) | 24.1 | 14.5 | 14.4 | 14.3 | 13.3 | 12.9 | 11.1 | 7.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|